Company / PP&E (Net)
Matinas BioPharma Holdings, Inc. PP&E (Net) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$468.0K
FY2024
5-year range
$468.0K / $2.1M
FY2020-FY2024
Trend
-75.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has fluctuated over the past 10 years, ranging from $356,143 in FY2016 to $2M in FY2022.
Based on SEC 10-K filings.
$468,000 in FY2024 with a 5-year CAGR of -23.2%.
Declined from $2M to $468,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -32.7%
- 5-Year CAGR
- -23.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -23.2%, indicating a declining trend.
- In FY2024, pp&e (net) decreased 75.7% year-over-year.
- Peak pp&e (net) was recorded in FY2022.
- Lowest pp&e (net) in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $468.0K | -75.7% |
| FY2023 | $1.9M | -8.0% |
| FY2022 | $2.1M | +36.0% |
| FY2021 | $1.5M | +0.9% |
| FY2020 | $1.5M | -12.9% |
| FY2019 | $1.7M | -14.4% |
| FY2018 | $2.0M | +30.1% |
| FY2017 | $1.6M | +340.8% |
| FY2016 | $356.1K | -5.7% |
| FY2015 | $377.7K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026